Is a calcineurin inhibitor required as part of the immunosuppression scheme in kidney transplant recipients that share 2-haplotypes with their donors?;¿Es necesario un inhibidor de calcineurina como parte del esquema de inmunosupresión en receptores de trasplante renal que comparten dos haplotipos con su donador?

Revista de Investigacion Clinica

Volumn 62, Issue 3, 2010, Pages 200-205

  Vega, Olynka ^a   Pérez Gutiérrez, Angélica ^a   Hernández Ordóñez, Sergio ^a   Correa Rotter, Ricardo ^a   Alberú, Josefina ^a   Morales Buenrostro, Luis E ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Calcineurin inhibitor; Double immunosuppressive therapy; Immunologic risk; Kidney transplant; Two haplotypes

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; COMPARATIVE STUDY; DONOR; DRUG ANTAGONISM; DRUG COMBINATION; IMMUNOLOGY; RETROSPECTIVE STUDY;

ADULT; CALCINEURIN; DRUG THERAPY, COMBINATION; FEMALE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 77956147669     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351(26): 2715-29.
2. Yang H. Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance. Am J Kidney Dis 2006; 47(4 Suppl. 2): S37-S51.
3. Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004; 36(2 Suppl.): S13-S15.
4. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008; 86(6): 761-7.
5. Opelz G, Wujciak T, Döhler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999; 1(3): 334-42.
6. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346(8): 580-90.
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349(24): 2326-33.
8. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78(4): 557-65.
9. Câmara NO, Dias MF, Pacheco-Silva A. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients. Clin Transplant 2004; 18(4): 450-5.
10. Opelz G; Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365(9470): 1570-6.